Oxidation phenotype and the metabolism and action of beta-blockers
- 1 April 1985
- journal article
- review article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 63 (7) , 285-292
- https://doi.org/10.1007/bf01731972
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Oxidation Phenotype and Beta-BlockersNew England Journal of Medicine, 1983
- Oxidation Phenotype — A Major Determinant of Metoprolol Metabolism and ResponseNew England Journal of Medicine, 1982
- Influence of renal failure on the hepatic clearance of bufuralol in manJournal of Pharmacokinetics and Biopharmaceutics, 1980
- Clinical Pharmacokinetics of MetoprololClinical Pharmacokinetics, 1980
- The Effect of Impaired Renal Function on the Plasma Concentration and Urinary Excretion of Metoprolol MetabolitesClinical Pharmacokinetics, 1980
- Plasma levels and β-blocking effect of α-hydroxymetoprolol—Metabolite of metoprolol—in the dogJournal of Pharmacokinetics and Biopharmaceutics, 1979
- Determination of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detectionJournal of Mass Spectrometry, 1976
- Clinical Pharmacokinetics of β-Adrenoreceptor Blocking DrugsClinical Pharmacokinetics, 1976
- Pharmacokinetic studies on the selectiveβ 1-receptor antagonist metoprolol in manJournal of Pharmacokinetics and Biopharmaceutics, 1974